GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (FRA:NPJP) » Definitions » Total Liabilities

Nephros (FRA:NPJP) Total Liabilities : €2.98 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Nephros Total Liabilities?

Nephros's Total Liabilities for the quarter that ended in Mar. 2024 was €2.98 Mil.

Nephros's quarterly Total Liabilities increased from Sep. 2023 (€2.15 Mil) to Dec. 2023 (€3.21 Mil) but then declined from Dec. 2023 (€3.21 Mil) to Mar. 2024 (€2.98 Mil).

Nephros's annual Total Liabilities declined from Dec. 2021 (€2.57 Mil) to Dec. 2022 (€2.00 Mil) but then increased from Dec. 2022 (€2.00 Mil) to Dec. 2023 (€3.21 Mil).


Nephros Total Liabilities Historical Data

The historical data trend for Nephros's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Total Liabilities Chart

Nephros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.55 2.41 2.57 2.00 3.21

Nephros Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 1.60 2.15 3.21 2.98

Nephros Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nephros's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.938+(1.275+-0.00099999999999967
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=3.21

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=10.877-7.664
=3.21

Nephros's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.775+(1.202+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.98

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=10.503-7.526
=2.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nephros Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nephros's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Nephros (FRA:NPJP) Business Description

Traded in Other Exchanges
Address
380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.

Nephros (FRA:NPJP) Headlines

No Headlines